INTRODUCTION
Immune checkpoint blockade has transformed oncology with the potential for durable responses even in patients with metastatic disease. Approved indications for immune checkpoint blockade in rare tumors are limited to Merkel cell carcinoma, cutaneous squamous cancers, and microsatellite-unstable malignancies (1) . Rare cancer histologies, collectively representing approximately a quarter of all cancers diagnosed, remain understudied and the efficacy of immune checkpoint blockade in these patient populations is unknown.
Neuroendocrine neoplasms represent a rare histologic subset of tumors with complex classification criteria dependent on the putative organ of origin, precluding a single taxonomy across anatomic sites (2) . The World Health Organization (WHO) and European Neuroendocrine Tumour Society (ENETS) have developed a classification scheme reflected in the most recent staging guidelines (Appendix Table 1 ) and was utilized in our study. Neuroendocrine neoplasms can develop throughout the body, with pancreatic neuroendocrine tumors (PNET) in particular having unique biological and clinical characteristics resulting in additional therapies being utilized for PNETs. Thus, PNETs are assessed in a separate cohort within S1609, currently accruing. Clinical trials for neuroendocrine neoplasms, particularly in high-grade neuroendocrine carcinomas, have been difficult to conduct due to the rarity of the disease, difficulties in precise classification, and a lack of robust predictive biomarkers for therapeutic efficacy. In this study we evaluated the 6 combination of ipilimumab and nivolumab in patients with diverse histologic sites and across tumor grades. SWOG 1609 DART (Dual Anti-CTLA-4 & Anti-PD-1 blockade in Rare Tumors), a basket immunotherapy trial studying ipilimumab plus nivolumab across multiple cohorts of rare tumor histologic subtypes, was designed to address the question of the efficacy of these agents in these understudied populations. The combination of ipilimumab and nivolumab was selected over nivolumab alone due to the signalfinding nature of this study with small cohorts of rare tumors, with lower-dose ipilimumab chosen to balance tolerability with potential efficacy. The trial is currently open across the United States at 861 sites. We present here the clinical data of the (non-pancreatic) neuroendocrine cohort of SWOG 1609 (S1609) DART.
PATIENTS AND METHODS
The trial was conducted by SWOG, and the investigational agents were provided by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) under an NCI CRADA agreement with Bristol-Myers Squibb (BMS). All study subjects provided their voluntary, written informed consent using a document approved by the institution's human subject protection committee. The study was conducted in accordance with the Declaration of Helsinki. The protocol and all amendments were approved by SWOG, the NCI, the NCI central institutional review board (CIRB), and by the regulatory committees at the participating institutions.
The Caris analysis of neuroendocrine specimens is IRB exempt as all data were analyzed utilizing de-identified aggregate data. 7 
Rationale for Population:
Rare cancers, for the purposes of this study, were identified typically with an incidence of less than 6 in 100,000 per year (3) . Tumor grading was based on 2010 WHO criteria, pathology and grade were determined by review of local pathology reports by the study principal investigators. No central pathology review was performed. This cohort (Cohort 23) of S1609 is comprised of refractory neuroendocrine neoplasms, independent of histologic grade and organ of origin, with the exception of pancreatic neuroendocrine neoplasms, which were stratified to a different cohort due to unique biology and alternate standard of care therapies.
Well-differentiated, grade 3 neuroendocrine neoplasms were eligible for this cohort, and microsatellite instability (MSI) status was not available.
Patient Selection:
Eligible patients had (non-pancreatic) neuroendocrine neoplasms, had progressed following at least one line of standard systemic therapy, and did not have an approved or standard therapy available that had been shown to prolong overall survival. At enrollment, patients were required to be 18 years of age or older, have a Zubrod performance status of 0-2, adequate hematologic, hepatic, thyroid, adrenal axis, and renal function, with absolute neutrophil count ≥ 1,000/mcL, platelets ≥ 75,000/mcL, hemoglobin ≥ 8 g/dL, creatinine clearance ≥ 50 mL/min, total bilirubin ≤ 2.0 x institutional upper limit of normal (IULN), AST and ALT ≤ 3.0 x IULN, TSH or free T4 serum ≤ IULN, and normal adrenocorticotropic hormone (ACTH) ≤ IULN. Women of childbearing potential were required to have a negative serum pregnancy test, and subjects were required to practice adequate birth control during protocol participation.
Treatment and Monitoring:
Treatment consisted of nivolumab 240mg intravenously (IV) every 2 weeks and ipilimumab 1mg/kg IV every 6 weeks on a continuous schedule, with dose adjustments and brief breaks from therapy specified in the protocol for treatmentrelated toxicities. Patients were removed from study therapy for disease progression, symptomatic deterioration, treatment delay for any reason >56 days, unacceptable or immune-related toxicity with inability to decrease prednisone to < 10mg daily, or per patient request.
Patients were evaluated with a history and physical, laboratory analyses (complete blood count, comprehensive metabolic panel, thyroid stimulating hormone, free thyroxine, ACTH, cortisol, lipase), and toxicity assessment at least every 6 weeks at the beginning of each cycle. Imaging studies for disease assessment were performed pre-study, week 8, week 16, week 24, and then every 12 weeks until progression.
Statistical Methods and Outcomes:
The primary objective of this Phase II trial was to evaluate the overall response rate (ORR, confirmed complete and partial responses [CR and PR]) by RECIST v1.1 based on local site review. Our objective was to distinguish between a true ORR ≤5% (null hypothesis, as patients had failed all known active therapies) 9 versus ≥ 30% (alternative hypothesis, a potentially clinically meaningful difference in tumor response in refractory solid tumors). A Simon's two-stage design was used, which required an analysis on the first 6 eligible patients who received protocol therapy. If 1 or more of the 6 patients had a response (confirmed CR or PR), an additional 10 patients were to be accrued. The design specified 2 or more responses out of 16 patients would reject the null hypothesis (one-sided alpha = 13%, power = 87%). This cohort accrued more than 16 patients because, unexpectedly, accrual was faster than expected following the two-week closure notification and several additional patients were enrolled onto incorrect cohorts in S1609 and re-stratified into this cohort after SWOG review of local pathology reports prior to knowledge of clinical benefit or toxicity. Analysis of ORR by tumor grade was not pre-specified. The secondary objectives were to estimate progression-free survival (PFS), overall survival (OS), ORR by immune-related RECIST (iRECIST), PFS by iRECIST, and to assess toxicity. PFS was measured from the start of protocol therapy to the first date of progression by RECIST v1.1 or death by any cause, with patients last known to be alive without progression censored at the date of last contact. OS was measured from the date of study registration to the date of death by any cause, with patients last known to be alive censored at the date of last contact. PFS and OS estimates were calculated using the Kaplan-Meier method and compared using log-rank tests.
Confidence intervals for medians were constructed using the method of Brookmeyer and Crowley (4), and confidence intervals (CI) for point estimates (e.g. 6-month PFS) were calculated using the log-log transformation. CIs for the primary ORR analysis accounted for the two-stage design (5); exact binomial CIs were calculated for subgroups utilizing the R function 'get_CI' from the package OneArmPhaseTwoStudy. Fisher's exact test was used to compare subgroups. All analyses were performed using R version 3.4.3.
RESULTS

Patient Characteristics
Thirty-five patients from 22 National Clinical Trial Network (NCTN) institutions were registered between 4/13/2017-5/25/2018, with 32 patients meeting eligibility criteria and receiving protocol therapy who are summarized in ( Table 1) . Three patients were excluded from analyses: two who were ineligible one of whom had an ineligible histology, and the other with an inadequate washout period prior to treatment initiation; and one eligible patient refused protocol treatment after giving initial consent. Of the 32 eligible patients who received protocol therapy, the median age was 60 years (range 36-81). The most common sites of primary tumor were lung and small intestine (both n=6). Notably, 18 of the 32 patients (56%) had high-grade carcinoma. The median number of prior lines of therapy was 2 for both the entire cohort as well as for patients with high-grade disease.
Toxicities
Treatment-related adverse events are summarized in Table 2 , with 84.4% of patients experiencing an adverse event (AE), and 50% developing a grade 3-4 AE.
The most common AEs (across all grades and at least possibly related to treatment) were hypothyroidism (31%), fatigue (28%), nausea (28%), vomiting (25%), aspartate aminotransferase (AST) increase (25%), alkaline phosphatase increase (22%) and anorexia (22%). Six patients experienced Grade 4 events, two with sepsis (6%), two with increased lipase (6%), one with retinopathy (3%), and one with hyperglycemia (3%). Overall, 72% of patients developed an immune-related AE (irAE) of any grade on treatment, with 38% (N= 10) developing grade 3-4 irAEs.
The most common irAEs of any grade were hypothyroidism (31%) and AST increase (25%). The most common grade 3-4 irAEs were alanine aminotransferase (ALT) increase (9%) and AST increase, lipase increase, and encephalopathy (all 6%).
There were no treatment-related deaths.
Outcomes
Among 32 patients, the ORR was 25% (95%CI 13%-42%), with 3% (N= 1) of patients achieving CR and 22% (N= 7) attaining a PR (Table 3, Figure 1A) .
Altogether, 41% of patients had stable disease with 6% having stable disease >6 months and responses ongoing (Figure 1D) . Response rates were similar regardless of organ of origin (Figure 1B) Figure 1 ) and the median OS is 11 months 95% CI (6,∞ ¿ (Appendix Figure 2) .
6) with ongoing responses (Appendix
We also assessed patients with iRECIST. There was only one patient that differed significantly. This patient had intermediate-grade disease of small intestine origin and achieved a confirmed iPR (instead of progressive disease per RECIST v1.1). By RECIST v1.1 this patient had progressed 59 days after treatment initiation, but currently remains on study with clinical benefit 326+ days after treatment initiation with confirmed iPR.
DISCUSSION
Neuroendocrine neoplasms represent a histologically and molecularly heterogeneous constellation of rare cancers that can arise across various organ types. Low-and intermediate-grade well-differentiated neuroendocrine neoplasms overexpress somatostatin receptors, which can be utilized both for functional imaging as well as therapeutic targeting with long-acting somatostatin analogs (6) .
In contrast, high-grade neuroendocrine carcinomas typically have more aggressive biology and minimal expression of somatostatin receptors and are typically treated with chemotherapy (7) . 177 Lu-Dotatate has recently shown activity with an 18% response rate for somatostatin-positive (low/intermediate grade) midgut neuroendocrine tumors and has attained Food and Drug Administration approval (8) . 13 To date, immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 has not been prospectively studied broadly across rare tumors, or in combination for neuroendocrine neoplasms. Prior studies of anti-PD-1 directed monotherapy have had limited efficacy across the spectrum of neuroendocrine neoplasms (9),(10), (11) , (12) , (13) . For this trial, the combination of ipilimumab with nivolumab was chosen to maximize response rates in signal finding cohorts relative to monotherapy, and the dose of ipilimumab of 1mg/kg IV every 6 weeks was chosen to minimize toxicity while retaining combinatorial efficacy based on published comparative data in other tumor types (14) . In the non-pancreatic neuroendocrine cohort of S1609 reported here, 25% of patients had a response to ipilimumab plus nivolumab, with no difference in ORR relative to organ of origin in our small cohort with a myriad of primary sites of origin (Figure 1B) . None of the lung tumors in our cohort were small-cell lung cancer, for which anti-PD-1 and anti-CTLA-4 have previously been investigated (15) , (16) , (17) . Of note, 44% of patients with highgrade neuroendocrine carcinomas had an objective response to therapy (Figure 2) .
Overall, this regimen resulted in no grade 5 toxicities, a <10% rate of grade 3-4 immune-related colitis and hepatitis, and no reported pneumonitis in this cohort.
However, serious treatment-related toxicity occurred in 37.5% of patients and treatment discontinuation due to grade 3-4 toxicities occurred in 31.5% of patients.
With responses across different primary tumor sites and a signal towards improved response in high-grade neuroendocrine carcinomas, a potential predictive biomarker to help select for patients who may derive preferential benefit from immune checkpoint blockade is crucial. Biomarker analyses are underway for 14 patients in the neuroendocrine cohort with a focus on PD-L1 expression by immunohistochemistry, tumor mutational burden, and comprehensive transcriptomic profiling given relevance in other tumor types (18) , (19) . One prior study found that high-grade gastroenteropancreatic neuroendocrine carcinomas had a higher rate of PD-L1 expression relative to lower-grade tumors, and was associated with poorer survival (20) . Poorly-differentiated neuroendocrine carcinoma may also have a higher mutational burden than lower-grade tumors (21, 22) . Clinically, anecdotal response to anti-PD-1 has been reported in high-mutational burden neuroendocrine carcinoma previously (23) .
Additionally, PD-L1 by IHC and tumor mutational burden in both tissue and blood have been associated with improved response to anti-PD-1 therapy across tumor types (18) , (24, 25) , (26) . Host factors related to HLA-type, immune status, microbiome and underlying etiology likely play a key role in influencing response to immune checkpoint blockade. To better understand the potential molecular basis for immunotherapeutic response, we assessed TMB and PD-L1 IHC in an independent cohort of neuroendocrine neoplasms not from S1609. While PD-L1 IHC was not different in high-grade versus intermediate/low-grade tumors, high-grade neuroendocrine tumors had a significantly greater rate of high TMB relative to intermediate/low-grade tumors, independent of site of origin (Appendix Table 2 ).
Thus, TMB merits additional evaluation as a biomarker to potentially discriminate response to combinatorial immune checkpoint blockade, which will be specifically assayed in this cohort through whole-exome sequencing. Overexpression of PD-L1 in high-grade neuroendocrine carcinomas of the lung has also been reported (27) . 15 The TMB landscape in large cell neuroendocrine tumor of lung (n=353) had been previously investigated and the median TMB found to be higher than in small cell lung cancer and non-small cell lung cancer (28) .
Strengths of this study include a broad population of patients across various tumor types representing both academic and community site accrual across the US, and support from the NCI, SWOG, and patient advocacy groups. Weaknesses of this study include its non-randomized nature, small sample size, and heterogenous patient population, which limit outcome comparisons between subgroups.
Additionally, central pathology review was not mandated, and grading of tumor was done locally and most often with Ki67 measurement. Local pathology and imaging response assessments were utilized.
As studied in SWOG 1609, a basket rare tumor immunotherapy trial, ipilimumab plus nivolumab has clinical activity in non-pancreatic neuroendocrine neoplasms, in particular high-grade neuroendocrine carcinomas, across numerous primary originating organ sites. Ongoing studies focused on high-grade neuroendocrine carcinoma with rigorous correlative science to better understand host and tumor characteristics of immunotherapeutic response are underway. 
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